137 related articles for article (PubMed ID: 21737670)
1. Expression of p53, Ki-67, E-cadherin, N-cadherin and TOP2A in triple-negative breast cancer.
Nakagawa M; Bando Y; Nagao T; Morimoto M; Takai C; Ohnishi T; Honda J; Moriya T; Izumi K; Takahashi M; Sasa M; Tangoku A
Anticancer Res; 2011 Jun; 31(6):2389-93. PubMed ID: 21737670
[TBL] [Abstract][Full Text] [Related]
2. Among triple-negative breast cancers, HER2(0) breast cancer shows a strong tendency to be basal-like compared with HER2(1+) breast cancer: preliminary results.
Nakagawa M; Bando Y; Nagao T; Takai C; Ohnishi T; Honda J; Moriya T; Izumi K; Takahashi M; Tangoku A; Sasa M
Breast Cancer; 2012 Jan; 19(1):54-9. PubMed ID: 21465226
[TBL] [Abstract][Full Text] [Related]
3. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry.
Park S; Koo JS; Kim MS; Park HS; Lee JS; Lee JS; Kim SI; Park BW
Breast; 2012 Feb; 21(1):50-7. PubMed ID: 21865043
[TBL] [Abstract][Full Text] [Related]
4. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications.
Rudolph P; Olsson H; Bonatz G; Ratjen V; Bolte H; Baldetorp B; Fernö M; Parwaresch R; Alm P
J Pathol; 1999 Jan; 187(2):207-16. PubMed ID: 10365096
[TBL] [Abstract][Full Text] [Related]
5. Expression of tissue inhibitor of matrix metalloproteinases (TIMP)-3 protein in invasive breast carcinoma: relation to tumor phenotype and clinical outcome.
Mylona E; Magkou C; Giannopoulou I; Agrogiannis G; Markaki S; Keramopoulos A; Nakopoulou L
Breast Cancer Res; 2006; 8(5):R57. PubMed ID: 17032447
[TBL] [Abstract][Full Text] [Related]
6. Topoisomerase IIalpha expression in breast cancer: correlation with outcome variables.
Depowski PL; Rosenthal SI; Brien TP; Stylos S; Johnson RL; Ross JS
Mod Pathol; 2000 May; 13(5):542-7. PubMed ID: 10824926
[TBL] [Abstract][Full Text] [Related]
7. Hormone receptor status rather than HER2 status is significantly associated with increased Ki-67 and p53 expression in triple-negative breast carcinomas, and high expression of Ki-67 but not p53 is significantly associated with axillary nodal metastasis in triple-negative and high-grade non-triple-negative breast carcinomas.
Han JS; Cao D; Molberg KH; Sarode VR; Rao R; Sutton LM; Peng Y
Am J Clin Pathol; 2011 Feb; 135(2):230-7. PubMed ID: 21228363
[TBL] [Abstract][Full Text] [Related]
8. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study.
Joensuu H; Isola J; Lundin M; Salminen T; Holli K; Kataja V; Pylkkänen L; Turpeenniemi-Hujanen T; von Smitten K; Lundin J
Clin Cancer Res; 2003 Mar; 9(3):923-30. PubMed ID: 12631589
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of topoisomerase 2A expression and gene change in operable invasive breast cancer.
Qiao JH; Jiao DC; Lu ZD; Yang S; Liu ZZ
Tumour Biol; 2015 Sep; 36(9):6833-8. PubMed ID: 25846735
[TBL] [Abstract][Full Text] [Related]
10. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
[TBL] [Abstract][Full Text] [Related]
11. Correlation between p53 and epidermal growth factor receptor expression in breast cancer classification.
Wang XZ; Liu Q; Sun JJ; Zuo WS; Hu DW; Ma SG; Mu DB; Yu ZY
Genet Mol Res; 2015 Apr; 14(2):4282-90. PubMed ID: 25966200
[TBL] [Abstract][Full Text] [Related]
12. The predictive role of E-cadherin and androgen receptor on in vitro chemosensitivity in triple-negative breast Cancer.
Koo JS; Jung W; Jeong J
Jpn J Clin Oncol; 2009 Sep; 39(9):560-8. PubMed ID: 19531543
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological Significance of the Proliferation Markers Ki67, RacGAP1, and Topoisomerase 2 Alpha in Breast Cancer.
Şahin S; Işık Gönül İ; Çakır A; Seçkin S; Uluoğlu Ö
Int J Surg Pathol; 2016 Oct; 24(7):607-13. PubMed ID: 27284123
[TBL] [Abstract][Full Text] [Related]
14. Expression of E-cadherin, beta-catenin, CD44s and CD44v6 in gastric adenocarcinoma: relationship with lymph node metastasis.
Joo M; Lee HK; Kang YK
Anticancer Res; 2003; 23(2B):1581-8. PubMed ID: 12820426
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of immunohistochemical expression of topoisomerase alpha II, MIB-1, p53, E-cadherin, retinoblastoma gene protein product, and HER-2/neu in adrenal and extra-adrenal pheochromocytomas.
Gupta D; Shidham V; Holden J; Layfield L
Appl Immunohistochem Mol Morphol; 2000 Dec; 8(4):267-74. PubMed ID: 11127918
[TBL] [Abstract][Full Text] [Related]
16. The expression of cytokeratin 5/6 in invasive lobular carcinoma of the breast: evidence of a basal-like subset?
Fadare O; Wang SA; Hileeto D
Hum Pathol; 2008 Mar; 39(3):331-6. PubMed ID: 18261623
[TBL] [Abstract][Full Text] [Related]
17. Expression of the apoptosis-related genes Bcl-2 and p53 in clinical samples from endometrial carcinoma patients.
González-Rodilla I; Verna V; Muñoz AB; Estévez J; Boix M; Schneider J
Anticancer Res; 2011 Dec; 31(12):4191-3. PubMed ID: 22199279
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma.
Tomsová M; Melichar B; Sedláková I; Steiner I
Gynecol Oncol; 2008 Feb; 108(2):415-20. PubMed ID: 18037158
[TBL] [Abstract][Full Text] [Related]
19. Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis.
Wong KK; Lu KH; Malpica A; Bodurka DC; Shvartsman HS; Schmandt RE; Thornton AD; Deavers MT; Silva EG; Gershenson DM
Int J Gynecol Pathol; 2007 Oct; 26(4):404-9. PubMed ID: 17885490
[TBL] [Abstract][Full Text] [Related]
20. Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers.
Toyama T; Yamashita H; Kondo N; Okuda K; Takahashi S; Sasaki H; Sugiura H; Iwase H; Fujii Y
BMC Cancer; 2008 Oct; 8():309. PubMed ID: 18950515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
